Glutaminolysis (GLS) and Metabolic Dependency

GLS makes glutamate. Which second step follows determines what the inhibitor does.

Two Isoforms, Two Products

EnzymeGeneProductNote
GLS1, long form (KGA)GLSGlutamate + NH₄⁺Mitochondrial; the form most often targeted
GLS1, short form (GAC)GLSGlutamate + NH₄⁺Alternatively spliced; lacks the N-terminal domain
GLS2GLS2Glutamate + NH₄⁺Liver and brain; often tumour-suppressive context

Important distinction. GLS produces glutamate, not α-ketoglutarate. The second step has two routes: glutamate dehydrogenase (GLUD1) releases ammonia and produces α-KG, while transaminases (GOT1/2, GPT, PSAT1) transfer the amino group to a keto acid and produce α-KG without releasing ammonia. The two routes differ in nitrogen handling and in the redox consequences, and a cell can switch between them.

This is why GLS inhibition does not always reduce α-KG supply to the extent expected: transaminase routes can sustain α-KG production from glutamate derived elsewhere, and glutamate can also be imported.

Part 1 — What Glutamine Is Used For

UseRouteConsequence of GLS inhibition
AnaplerosisGLS → glutamate → α-KG → TCAReduced TCA intermediates; depends on alternative anaplerosis
Nitrogen donorAmide N for nucleotides; amino N for transaminationReduced nucleotide synthesis; amino acid imbalance
Glutathione synthesisGlutamate exported via SLC7A11 for cystine importReduced cystine uptake and GSH, in cells dependent on this route
Reductive carboxylationGlutamine → α-KG → citrate via IDH2, in hypoxiaImpaired lipogenesis from glutamine
SignallingIntracellular glutamine and exchange-dependent leucine uptakeReduced mTORC1 signalling

Readout note. GLS inhibition affects all five. A phenotype after CB-839 therefore does not establish that anaplerosis was the relevant role. The discriminating experiments are rescues: cell-permeable α-KG for anaplerosis, nucleosides for nucleotide synthesis, NAC or β-mercaptoethanol for the glutathione route, and leucine for the exchange-dependent signalling route.

Part 2 — When Glutamine Becomes a Dependency

Dependency is a property of the medium and the cell together, not of the cell alone.

ConditionEffect on glutamine dependence
High medium glutamine (4 mM)Cells can often survive GLS inhibition by importing glutamate
Low medium glutamine (0.5–1 mM)GLS becomes more important; dependence appears
Absent or low glucoseGlutamine oxidation supports the TCA cycle; dependence rises
HypoxiaReductive carboxylation dominates; GLS still required, IDH2 direction changes
High proliferation rateNucleotide demand rises; amide nitrogen requirement rises
Expression of alternative anaplerotic routesPyruvate carboxylation or propionyl-CoA can substitute

Caveat on the standard experiment. Most glutamine-dependency work is performed in medium containing 2–4 mM glutamine, which is several-fold above plasma concentrations. A dependency demonstrated at 4 mM is a stronger claim than one demonstrated at 0.5 mM, because the higher concentration means the cell had more alternative substrate available. Reporting the concentration is therefore part of the finding.

Part 3 — Reductive Carboxylation

In hypoxia or when mitochondrial function is impaired, glutamine-derived α-KG can be converted to citrate by the reverse reaction of isocitrate dehydrogenase 2, supplying acetyl-CoA equivalents for lipogenesis.

FeatureOxidative routeReductive route
Direction of IDH2Forward (citrate → α-KG)Reverse (α-KG → citrate)
Oxygen requirementHighLow
Carbon labelling patternGlutamine carbon into malate and aspartateGlutamine carbon into citrate m+5, and into fatty acids
Readout¹³C-glutamine into malate¹³C-glutamine into citrate and palmitate

Important distinction. The same tracer produces different labelling patterns depending on direction, which is why tracing — not enzyme expression — identifies the route. MTHFD2 expression, IDH2 expression and hypoxia markers are all consistent with either direction.

Part 4 — Testing a GLS Dependency

StepMeasurementWhat it establishes
1Glutamine consumption and glutamate releaseThat glutaminolysis is active
2¹³C-glutamine into TCA intermediatesThat carbon enters the cycle
3GLS1 knockdown plus CB-839That the effect is on-target
4Growth in reduced glutamineThat the requirement is concentration-dependent
5Rescue panel: α-KG, nucleosides, NAC, leucineWhich role mattered
6Ammonia measurementWhether nitrogen disposal changed

The fifth step is the one that converts the result into a mechanism, and the fourth is what makes it quantitative. A dependency that disappears at 4 mM glutamine but is present at 1 mM is a real dependency in the latter condition and should be reported as such.

Part 5 — Model Requirements and Recurring Failures

RequirementWhy
Medium glutamine concentration statedIt determines the dependency
Medium age recordedGlutamine degrades to ammonia at 37 °C
Glucose concentration statedIt competes with glutamine for the TCA cycle
Ammonia measuredA product and a signal
Proliferation measuredDemand scales with biomass
Transaminase route consideredIt can substitute for GDH

Recurring failures:

  • • "GLS produces α-KG" stated as a single step, hiding the transaminase alternative.
  • • CB-839 used at a single high concentration without an on-target control.
  • • Rescue with α-KG at millimolar concentrations without considering osmotic and metabolic effects.
  • • Dependency claimed at 4 mM glutamine and generalised to physiological conditions.
  • • Ammonia not measured, although glutaminolysis is its main source in culture.
  • • Reductive carboxylation inferred from expression rather than from labelling direction.
  • • Glutamate import ignored, although it can bypass GLS entirely.

Part 6 — Where This Article Connects

This is the glutaminolysis article of the amino acid cluster, and it takes the pillar's five-role framework and applies it to one enzyme. The CB-839 protocol article covers dosing; the glutamine concentration article covers the medium variable that determines whether a dependency exists at all; the nucleotide and one-carbon articles cover the two downstream consumers that most often explain the phenotype.

If you need glutaminolysis measured with route-resolved tracing and a rescue panel, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

GLS isoform expression, transaminase use and dependency vary with cell type, medium composition, oxygen tension and proliferation. The conditions here describe principles, not thresholds for a specific model.

Inhibition of glutaminolysis does not establish which glutamine role was required, and a dependency demonstrated in one medium does not transfer to another.

Scientific interpretation and experimental design

  • • GLS makes glutamate. α-KG needs a second step.
  • • Two second steps. GDH releases ammonia; transaminases do not.
  • • Dependency depends on the medium. State the glutamine concentration.
  • • Reductive carboxylation is a labelling pattern. Expression cannot identify direction.
  • • Rescue panel, not rescue compound. One rescue tests one role.
  • • Ammonia is the product. Measure it.

Selected references for further reading

  • • DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313–324.
  • • Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer. 2016;16:619–634.
  • • Metallo CM, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380–384.
  • • Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385–388.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: